An inexpensive home meter to monitor CKD and heart failure directly in a drop of blood

点击翻译按钮获取中文摘要

Empowering patients to make timely and appropriate decisions regarding their health can fundamentally change the consumption of healthcare. For example, recent advances in continuous glucose monitoring have enabled insulin-dependent diabetes patients to titrate their insulin dosing and hence achieve tighter glycemic control in a sustained manner. There is an opportunity to drive similar diagnostic-based disruption in Chronic Kidney Disease (CKD), Heart Failure (HF) and even inflammation or immune response mediated diseases such as Coronary Vascular Disease (CVD) and celiac disease (CD). The Vallée-Bélisle lab at the University of Montreal recently reported and patented a family of electrochemical DNA-based assays that can deliver lab quality measurements at home from one drop of whole blood, thereby enabling the patient to titrate its therapy in real-time. The proposed project will provide scientific and engineering evidence establishing the technical feasibility to develop a prototype electrochemical DNA-based sensor and will develop this prototype for the detection of 3 key markers for monitoring CKD and HF at home.